Loading clinical trials...
Loading clinical trials...
An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma
Conditions
Interventions
Tenalisib
Romidepsin
Locations
15
United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of California, Hellen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
University of Miami-Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Rush University Cancer Center
Chicago, Illinois, United States
Start Date
March 12, 2019
Primary Completion Date
May 14, 2021
Completion Date
May 14, 2021
Last Updated
October 28, 2022
NCT05475925
NCT05414500
NCT07470996
NCT05589896
NCT07389616
NCT07356245
Lead Sponsor
Rhizen Pharmaceuticals SA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions